Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A phase I, open-label, dose-finding study to assess the safety, tolerability and
pharmacokinetics of ISU104, a human monoclonal antibody targeting erbB3 in patients with
advanced solid tumors.